The starting point: what kind of problem is gastritis?
Chronic gastritis is a disease of inflammation — specifically, an immune response to bacterial colonisation of the stomach wall. H. pylori, present in a significant majority of Indian endoscopy patients, colonises the gastric mucosa and activates a persistent inflammatory cascade through NF-kB, IL-8, and immune cell infiltration that physically damages the mucosal tissue.[1]
Acid is not the cause of this inflammation. It is a secondary factor — when the mucus layer thins due to goblet cell damage, the underlying epithelium is exposed to stomach acid at concentrations it cannot handle. The result is burning. But the burning is a consequence of the mucosal damage, not the cause of it.
This distinction is the foundation of the entire comparison that follows.
Why antacids keep being taken — and why they keep not working
The pattern is consistent across Indian gastritis patients. Symptoms appear. The patient takes an antacid — Gelusil, Digene, Eno. Relief comes within minutes because the acid is neutralised. The burning stops. The patient concludes the problem is acid. The next time symptoms return, the antacid is taken again.
Meanwhile, the actual gastritis — the H. pylori-driven mucosal inflammation — continues undisturbed. The antacid addresses the symptom expression (burning from acid on inflamed tissue) with no effect on the underlying biology (bacteria, NF-kB, IL-8, mucosal thinning). The relief is real. The problem it addresses is real. But it is a narrow slice of a larger problem.
CagA toxin injection and outer membrane protein binding trigger persistent NF-kB activation in gastric epithelial cells. This runs continuously while H. pylori is present.
NF-kB activates transcription of IL-8, TNF-α, IL-1β. These cytokines recruit neutrophils and lymphocytes into the mucosal tissue, causing direct cellular damage.
Goblet cell damage reduces mucus production. The protective gel layer thins. Stomach acid reaches the inflamed epithelium, producing the burning pain the patient feels.
The antacid neutralises the acid. The symptom (burning) resolves. H. pylori, NF-kB, IL-8, and the mucosal thinning are all exactly as they were. The cycle restarts.
CagA toxin injection and outer membrane protein binding trigger persistent NF-kB activation in gastric epithelial cells. This runs continuously while H. pylori is present.
NF-kB activates transcription of IL-8, TNF-α, IL-1β. These cytokines recruit neutrophils and lymphocytes into the mucosal tissue, causing direct cellular damage.
Goblet cell damage reduces mucus production. The protective gel layer thins. Stomach acid reaches the inflamed epithelium, producing the burning pain the patient feels.
The antacid neutralises the acid. The symptom (burning) resolves. H. pylori, NF-kB, IL-8, and the mucosal thinning are all exactly as they were. The cycle restarts.
The mechanism comparison
Here is where antacids, PPIs, and TumGard each operate — against the biology of chronic H. pylori-driven gastritis:
| Mechanism | Antacid / PPI | TumGard |
|---|---|---|
| H. pylori urease inhibition | ✗ No effect. PPIs may slightly reduce colonisation but do not inhibit urease directly. | ✓ Yes. Quercetin and myricetin directly inhibit H. pylori urease, reducing acid-survival capacity. |
| NF-kB inflammatory cascade | ✗ Not addressed. Acid suppression does not interact with NF-kB signalling, IL-8 production, or neutrophil infiltration in any way. | ✓ Yes. Quercetin inhibits NF-kB activation in gastric epithelial cells, reducing IL-8 and TNF-α production. |
| EGFR/ERK mucosal repair | ✗ Not activated. PPIs have no EGFR/ERK signalling activity and do not trigger goblet cell regeneration or mucus layer rebuilding. | ✓ Yes. Licorice-derived glabridin activates EGFR/ERK signalling in goblet cells, triggering mucus synthesis and epithelial regeneration. |
| Acid suppression / symptom relief | ✓ Yes. This is what they are designed for — and they do it well. Antacids: rapid, short-term. PPIs: sustained 24–48 hour suppression. | ✗ Not the design. TumGard reduces the inflammatory load that makes the tissue acid-sensitive, but does not suppress acid production directly. |
| Risk of rebound symptoms | High on stopping. Parietal cell hyperplasia during PPI use causes above-normal acid production when the PPI is discontinued. | Not applicable. TumGard does not suppress acid production, so there is no rebound hypersecretion effect when discontinued. |
What TumGard is actually doing in the stomach
TumGard's formula is built around three active flavonoid mechanisms that target the gastritis cascade at its source rather than at its symptom expression:
Quercetin and myricetin bind to H. pylori's urease enzyme, blocking the ammonia-producing reaction the bacteria uses to survive stomach acid. Without urease activity, H. pylori cannot maintain the pH microenvironment it needs to colonise the mucosal wall.[3]
Quercetin stabilises IκB — the protein that keeps NF-kB inactive — and inhibits the IKK kinase complex that triggers its release. This reduces transcription of IL-8, TNF-α, and IL-1β, decreasing the cytokine load driving mucosal damage.[3]
Licorice-derived glabridin activates EGFR receptor signalling and the downstream ERK1/2 phosphorylation cascade in goblet cells — triggering mucin synthesis, goblet cell proliferation, and epithelial surface regeneration.[2]
TumGard and a PPI operate at different points in the gastritis biology. A PPI reduces the acid that burns an already-inflamed surface. TumGard reduces the inflammation making the surface vulnerable in the first place and supports its repair. Used together, they cover more of the problem than either alone.
The long-term picture
Chronic PPI use beyond 8–12 weeks comes with documented concerns in the literature — increased risk of Clostridioides difficile infection, potential calcium and magnesium malabsorption, and emerging data on kidney and dementia risk with very long-term use.[1] These risks are not reasons to stop a medically appropriate PPI, but they are relevant context for patients who have been on continuous acid suppression for months or years without reassessment.
The 37% of TumGard's survey respondents who had been symptomatic for more than three years — most on some form of acid suppression throughout — represent a population managing a chronic condition that was never structurally addressed. The antacid was never designed to produce structural recovery. It was managing the symptom of a problem that continued to progress underneath it.
In a survey of 20,363 Indian adults with gut symptoms, 54% were on antacids or PPIs and still experiencing symptoms. 37% had been symptomatic for more than three years. Among respondents who had undergone endoscopy, only 5.8% had a completely normal result — 86% had a clinically significant finding. Most had been managing acid. Almost none had addressed H. pylori.
References
- Crowe SE. Helicobacter pylori infection. New England Journal of Medicine. 2019;380(12):1158–1165. PMID 30699316. Documents H. pylori NF-kB activation pathways and the limitations of PPI-only treatment in chronic gastritis. Also source of long-term PPI risk data cited in this article.
- Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defence and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41–60. PMID 18424695. Establishes EGFR/ERK as the primary mucosal repair pathway and documents its suppression in active H. pylori-driven gastritis — foundational to the repair mechanism comparison in this article.
- Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Modulating role of nuclear factor-κB in the gastroprotective action of flavonoids. Journal of Ethnopharmacology. 2023. PMID 36842733. Documents quercetin NF-kB inhibitory mechanism and glabridin EGFR/ERK activation in gastric tissue — the mechanistic basis for TumGard's scorecard in the comparison table.
- Merlin Annie Raj, RD. TumGard India Gut Health Report 2026. Hugg Beverages Pvt. Ltd. 2026. tumgard.com/india-gut-health-report-2026. Source of the 54% medicated-but-symptomatic figure, 37% three-year symptom duration, and 5.8% normal endoscopy rate cited in this article. Total survey n=20,363.
The 54% medicated-but-symptomatic rate is consistent with published literature documenting PPI inadequacy for H. pylori-driven gastritis when H. pylori is not co-addressed (Crowe, NEJM 2019). The mechanism comparison table reflects established pharmacology for PPIs and for TumGard's active compounds (Ye et al. 2023; Laine et al. 2008). The rebound hypersecretion risk on PPI discontinuation is a documented pharmacological effect, not a proprietary claim.